FCGR3A and leukemia: Compared to conventional NK cells, ML NK cells also have enhanced FcγRIIIa (CD16)-induced killing effects and attenuated inhibitory KIR signals, methods such as CD16A bi-specific engagers, NKG2A inhibitor and CAR engineering have achieved satisfied outcomes in Hodgkin lymphoma and leukemia [78–80].